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TO THE EDITOR
Generalized vitiligo is a disease in which patches of depigmented skin and overlying hair
result from autoimmune destruction of melanocytes in involved regions (Spritz, 2012).
Clinic-based studies cite high prevalence of vitiligo in India, up to 8.8% (e.g. Handa and
Kaur, 1999), though population-based surveys report much lower prevalence, 0.46% in
Calcutta (Das et al., 1985) and 1.79% in South Gujarat (Mehta et al., 1973).
Vitiligo is a distressing cosmetic problem in individuals of dark skin phototypes, due to
striking contrast between lesions and unaffected skin. This may explain the reported high
prevalence of vitiligo in India and negative impact on perceived quality of life in this
population (Parsad et al., 2003). Indeed, vitiligo has long been recognized in India (Singh et
al., 1974), the specific use of ultraviolet light treatment was pioneered in India (Menon,
1945), and some of the earliest genetic studies of vitiligo were carried out there: of ABO
blood groups, α1-antitrypsin, and haptoglobin, and subsequent candidate gene studies,
including GCH1, ACE, CAT, CTLA4, GPX1, IL4, MBL2, and PTPN22, most yielding
negative or conflicting results. Recently, Singh et al. (2012) tested genetic association of
vitiligo in Indian patients with HLA–A, -B, -C in the MHC class I region and HLA-DRB1 in
the class II region, identifying primary genetic association with HLA-DRB1* 07:01.
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Here, we describe a more comprehensive genetic association study of generalized vitiligo on
the Indian subcontinent, utilizing the Immunochip® (Cortes and Brown, 2011) to screen
196,524 SNPs in 128 loci previously implicated in autoimmune and inflammatory diseases,
including 9441 SNPs spanning the extended major histocompatibility complex (MHC) on
chromosome 6p. Our results suggest there are at least two independent association signals in
the MHC class II region, one located upstream of HLA-DRA and the other located between
HLA-DRB1 and HLA-DQA1, generally similar to what we previously found in a
genomewide association study of vitiligo in European-derived whites (EUR) (Jin et al.,
2010).
Our initial study group consisted of 255 patients with generalized vitiligo and 377 unrelated
non-vitiligo controls of Indian subcontinent (Pakistan, India, Sri Lanka, Bangladesh)
derivation. After quality control procedures, data for 120,724 remaining SNPs from 251
remaining cases were compared to those from 349 remaining controls. Suggestive
association signals were considered as clusters of nearby SNPs with trend P-values <10−5.
The International Immunochip Consortium has agreed on a genomewide significance
criterion of P<5 × 10−8 for studies utilizing the Immunochip (Cortes and Brown, 2011).
As shown in Figure 1a and Supplementary Table S1, the only highly suggestive association
signals were in the MHC class II gene region (Figure 1b), from rs3134942 (chr6:32168770)
to rs2856674 (chr6:32659644), spanning the upstream part of NOTCH4 through HLA-
DQB1. The principal region of association encompassed c6orf10--BTNL2--HLA-DRA--
HLA-DRB5--HLA-DRB1--HLA-DQA1 (Figure 1b), with extensive LD through this region
in this population (Figure 1c). One SNP, rs482044, located towards the centromeric end of
the region, between HLA-DRB1 and HLA-DQA1, achieved genomewide significance (G
allele; P=1.94 × 10−8, OR=1.93; Table 1), remaining significant (P = 4.86 × 10−8) even after
correction for the observed genomic inflation factor λ = 1.06.
To determine which SNPs in the MHC class II region represent primary association with
vitiligo versus are signals secondary to LD, we applied a backward regression procedure,
comparing a model including the seven most significant MHC class II SNPs to alternative
models in which each SNP was removed one by one. This analysis suggested that this region
contains two independent associated loci, one represented by rs482044-G (located between
HLA-DRB1 and HLA-DQA1) and the other represented by rs3129859-C (located 6680 nt
upstream of HLA-DRA). Forward regression analysis of these two SNPs showed that the
model composed of rs3129859 was significantly (P=4.4 × 10−5) improved by adding
rs482044, and that the model composed of rs482044 was significantly improved (P=6.0 ×
10−4) by adding rs3129859.
In contrast to our previous findings in EUR (Jin et al., 2010), we observed no apparent
association of vitiligo with SNPs in the MHC class I region in this Indian-Pakistani
population (Figures 1a and 1b). Furthermore, considering loci represented on the
Immunochip that have been reported to be associated with vitiligo in previous candidate
gene studies from India, no SNPs in the ACE (3 SNPs), CTLA4 (505 SNPs), or IL4 (103
SNPs) gene regions showed even nominal association in the present study.
To confirm association of generalized vitiligo with MHC class II region SNPs in the Indian
subcontinent, we carried out a replication study of rs3129859 and rs482044, as well as the
third most significant Immunochip SNP, rs3096691 (located just upstream of NOTCH4)
(Fig. 1b). These three SNPs were genotyped in 685 unrelated generalized vitiligo cases and
774 unrelated controls from Gujarat state, India. All three were in Hardy-Weinberg
equilibrium in the controls, and all three achieved at least nominal significance in the
replication study (Table 1). Most significant association in the replication study was
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observed for rs3129859-C (P=9.48 × 10−9), with no significant heterogeneity of OR between
the two studies (PBreslow-Day=1.15 × 10−1). Cochran-Mantel-Haenszel meta-analysis of the
rs3129859 data from the Immunochip screen and replication study likewise yielded
strongest overall association (P=4.30 × 10−14, OR=1.67; 95% C.I. 1.46–1.91). Association
was also confirmed in the replication study for rs482044 (P= 1.11 × 10−4), with only
nominal association for rs3096691 (P=2.32 × 10−2), although both of these SNPs exhibited
heterogeneity of OR. Both rs482044 (P=1.58 × 10−2) and rs3129859 (P = 1.20 × 10−6)
remained significant when each was conditioned on the other. Overall, our findings thus
generally confirm association of vitiligo with at least two independent loci in the MHC class
II region.
In a previous genomewide-association study of generalized vitiligo in EUR subjects, we
found that both vitiligo susceptibility (Jin et al., 2010) and age of onset (Jin et al., 2011) are
likewise associated with at least two independent loci in the MHC class II region. To assess
whether the MHC class II loci observed in the Indian subcontinent and EUR populations
might correspond ancestrally, we carried out trans-ethnic meta-analysis using MANTRA
(Morris, 2011), which indicated that the MHC association signal represented by rs482044 in
the Indian subcontinent population apparently corresponds to the MHC signal represented
by rs532098 in EUR (Jin et al., 2010) (Table S2). In contrast, rs3129859 is not significantly
associated with vitiligo in EUR (Jin et al., 2010), and correspondence between the
association signals upstream of HLA-DRA observed in both populations remains uncertain.
Our findings thus highlight both similarity and differences of vitiligo MHC genetic
associations in subjects from different major world populations. On the Indian subcontinent,
this study and that of Singh et al. (2012) support association of vitiligo with loci in the MHC
class II region, but show no primary association in the MHC class I region. Similarly, in the
EUR population, vitiligo is also associated with multiple signals in the MHC class II region,
at least one of which, between HLA-DRB1 and HLA-DQA1, appear to correspond to one in
the Indian subcontinent population. However, in the EUR population vitiligo shows primary
association with HLA-A in the distal class I region (Jin et al., 2010); specifically, HLA-
A*02:01 (Jin et al., 2011). In addition, studies in Chinese show principal MHC association
in the class III region (Quan et al., 2010) and in the proximal class I region, between HLA-B
and HLA-C (Liu et al., 2012). Together, these similarities and differences of principal MHC
genetic associations with generalized vitiligo among different populations may in part
underlie differing prevalence of this autoimmune disease in different groups around the
world.
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Figure 1. Immunochip association results for generalized vitiligo
(a) The distribution of −log10(P-values) from the Cochran-Armitage trend test is shown
plotted across the chromosomes for 120,274 SNPs that passed quality control filters in 251
cases and 349 controls. The dashed blue line indicates the genome-wide significance
criterion (P<5 × 10−8) that has been agreed for studies utilizing the Immunochip (Cortes and
Brown, 2011). (b) A genomic map of the extended MHC, including class I and class II
region of association, with the positions of rs3096691, rs3129859, and rs482044 indicated.
(c) Pattern of LD (D’) observed across the MHC class II region of association.
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